ArticleStem cells international2012
Cellular reprogramming employing recombinant sox2 protein.
Article in Stem cells international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 48 citations in OpenAlex.
- Review
- Generation of a recombinant version of a biologically active cell-permeant human HAND2 transcription factor from E. coli.Scientific reports · 2022Article
- Identification of Optimal Expression Parameters and Purification of a Codon-Optimized Human GLIS1 Transcription Factor from Escherichia coli.Molecular biotechnology · 2022Article
- Protein Production and Purification of a Codon-Optimized Human NGN3 Transcription Factor from E. coli.The protein journal · 2021Article
- Direct Reprogramming of Somatic Cells to Neurons: Pros and Cons of Chemical Approach.Neurochemical research · 2021Article
- A Concise Review on Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Personalized Regenerative Medicine.Stem cell reviews and reports · 2021Review
- Article
- Generation of a Recombinant Stem Cell-Specific Human SOX2 Protein from Escherichia coli Under Native Conditions.Molecular biotechnology · 2021Article
- Application of iPSC to Modelling of Respiratory Diseases.Advances in experimental medicine and biology · 2020Review
- Take the shortcut - direct conversion of somatic cells into induced neural stem cells and their biomedical applications.FEBS letters · 2019Review
- An Insight into DNA-free Reprogramming Approaches to Generate Integration-free Induced Pluripotent Stem Cells for Prospective Biomedical Applications.Stem cell reviews and reports · 2019Review
- Transdifferentiation: a new promise for neurodegenerative diseases.Cell death & disease · 2018Review
- Enhanced intracellular delivery via coordinated acoustically driven shear mechanoporation and electrophoretic insertion.Scientific reports · 2018Article
- Modeling Parkinson's Disease Using Patient-specific Induced Pluripotent Stem Cells.Journal of Parkinson's disease · 2018Review
- Cellular Reprogramming Using Protein and Cell-Penetrating Peptides.International journal of molecular sciences · 2017Review
- Nuclear delivery of recombinant OCT4 by chitosan nanoparticles for transgene-free generation of protein-induced pluripotent stem cells.Oncotarget · 2016Article
- Nanog induces suppression of senescence through downregulation of p27KIP1 expression.Journal of cell science · 2016Article
- Direct lineage conversion of astrocytes to induced neural stem cells or neurons.Neuroscience bulletin · 2015Review
- Non-viral methods for generating integration-free, induced pluripotent stem cells.Current stem cell research & therapy · 2015Review
- Generation of mouse induced pluripotent stem cells by protein transduction.Tissue engineering. Part C, Methods · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Induced pluripotent stem (iPS) cells represent an attractive option for the derivation of patient-specific pluripotent cells for cell replacement therapies as well as disease modeling. To become clinically meaningful, safe iPS cells need to be generated exhibiting no permanent genetic modifications that are caused by viral integrations of the reprogramming transgenes. Recently, various experimental strategies have been applied to accomplish transgene-free derivation of iPS cells, including the use of nonintegrating viruses, episomal expression, or excision of transgenes after reprogramming by site-specific recombinases or transposases. A straightforward approach to induce reprogramming factors is the direct delivery of either synthetic mRNA or biologically active proteins. We previously reported the generation of cell-permeant versions of Oct4 (Oct4-TAT) and Sox2 (Sox2-TAT) proteins and showed that Oct4-TAT is reprogramming-competent, that is, it can substitute for Oct4-encoding virus. Here, we explore conditions for enhanced Sox2-TAT protein stabilization and functional delivery into somatic cells. We show that cell-permeant Sox2 protein can be stabilized by lipid-rich albumin supplements in serum replacement or low-serum-supplemented media. Employing optimized conditions for protein delivery, we demonstrate that Sox2-TAT protein is able to substitute for viral Sox2. Sox2-piPS cells express pluripotency-associated markers and differentiate into all three germ layers.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.